Literature DB >> 8038869

Detection of an Alzheimer disease pattern of cerebral metabolism in Down syndrome.

N P Azari1, K D Pettigrew, P Pietrini, B Horwitz, M B Schapiro.   

Abstract

Correlational analysis of cerebral metabolic (rCMRglc) data obtained with positron emission tomography (PET) assesses group differences and has demonstrated reduced frontal-parietal rCMRglc interdependencies in Alzheimer's disease (AD). A multivariate analysis of rCMRglc data assesses individual differences. We recently identified discriminant functions, reflecting frontal-parietal rCMRglc interdependencies, that separated AD from control subjects. To test if the functions would identify an AD rCMRglc pattern in older Down syndrome (DS) adults with (DS DAT+) or without (DS DAT-) dementia, we applied the functions to longitudinal rCMRglc data in: young DS (n = 15), DS DAT- (n = 10), DS DAT+ (n = 4), and young controls (n = 15). All DS DAT+ and some of the later DS DAT- scans were classified as AD. The results provide additional validation of the functions and suggest their utility for the early detection of AD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8038869     DOI: 10.1159/000106700

Source DB:  PubMed          Journal:  Dementia        ISSN: 1013-7424


  7 in total

1.  Functional brain imaging to identify affected subjects genetically at risk for Alzheimer's disease.

Authors:  S I Rapoport
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia.

Authors:  Marwan N Sabbagh; Kewei Chen; Joseph Rogers; Adam S Fleisher; Carolyn Liebsack; Dan Bandy; Christine Belden; Hillary Protas; Pradeep Thiyyagura; Xiaofen Liu; Auttawut Roontiva; Ji Luo; Sandra Jacobson; Michael Malek-Ahmadi; Jessica Powell; Eric M Reiman
Journal:  Alzheimers Dement       Date:  2015-04-04       Impact factor: 21.566

3.  Preclinical stages in subjects at risk for neurological disorders: can PET-FDG tell us more?

Authors:  N P Azari; P Pietrini
Journal:  J Neurol       Date:  1995-01       Impact factor: 4.849

4.  Dissociation of Down syndrome and Alzheimer's disease effects with imaging.

Authors:  Dawn C Matthews; Ana S Lukic; Randolph D Andrews; Boris Marendic; James Brewer; Robert A Rissman; Lisa Mosconi; Stephen C Strother; Miles N Wernick; William C Mobley; Seth Ness; Mark E Schmidt; Michael S Rafii
Journal:  Alzheimers Dement (N Y)       Date:  2016-06

Review 5.  Metabolic and Vascular Imaging Biomarkers in Down Syndrome Provide Unique Insights Into Brain Aging and Alzheimer Disease Pathogenesis.

Authors:  Elizabeth Head; David K Powell; Frederick A Schmitt
Journal:  Front Aging Neurosci       Date:  2018-06-21       Impact factor: 5.750

6.  Distribution of microglial phenotypes as a function of age and Alzheimer's disease neuropathology in the brains of people with Down syndrome.

Authors:  Alessandra C Martini; Alex M Helman; Katie L McCarty; Ira T Lott; Eric Doran; Frederick A Schmitt; Elizabeth Head
Journal:  Alzheimers Dement (Amst)       Date:  2020-10-14

Review 7.  A Review of Functional Neuroimaging in People with Down Syndrome with and without Dementia.

Authors:  Funmi Deinde; Jay Kotecha; Lilian Suh Lih Lau; Sagnik Bhattacharyya; Latha Velayudhan
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2021-12-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.